Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
List view / Grid view
Spanish researchers have discovered that vitamin C may hold the key to improving the efficacy of dendritic cell-derived anticancer therapies.
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
Researchers in the US have found that antibodies to the SARS-CoV-2 Spike protein can be produced in hen eggs.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.